# Effect of parecoxib on postoperative cognitive function and analgesic safety in elderly patients undergoing gastrointestinal tumor resection: A retrospective study

**Authors:** Yongli Li, Yan Peng

PMC · DOI: 10.17305/bb.2024.11042 · Biomolecules and Biomedicine · 2024-09-16

## TL;DR

This study found that parecoxib reduces postoperative pain in elderly patients without worsening cognitive function or increasing complications.

## Contribution

The study demonstrates that parecoxib can alleviate postoperative pain without negatively affecting cognitive function or increasing complications in elderly patients.

## Key findings

- Parecoxib did not significantly reduce the incidence of postoperative cognitive dysfunction (POCD) in elderly patients.
- Patients receiving parecoxib experienced significantly less pain on the first and second days after surgery.
- Parecoxib did not increase postoperative complications or adverse events.

## Abstract

Neuroinflammation is associated with the development of postoperative cognitive dysfunction (POCD). Parecoxib has powerful anti-inflammatory and analgesic effects, which may reduce the occurrence of POCD. We hypothesized that parecoxib could reduce the incidence of POCD and relieve postoperative pain without increasing postoperative complications in elderly patients with gastrointestinal cancer. The study analyzed the effect of parecoxib on elderly patients undergoing elective radical resection of gastrointestinal tumors. Patients were divided into the non-steroidal anti-inflammatory drugs (NSAIDs) group and the non-NSAIDs group according to whether parecoxib was administered. Demographic and clinical data were collected and compared. The incidence of POCD was set as the primary outcome, and postoperative pain as the secondary outcome. Among the 440 enrolled patients, the POCD incidence rates within seven days after surgery in the NSAIDs and non-NSAIDs groups were 42.60% and 40.30%, respectively, with no statistically significant difference (P > 0.05). Patients in the NSAIDs group experienced significantly less pain on the first and second days after surgery compared to the non-NSAIDs group (P < 0.05). There were no statistically significant differences in postoperative adverse events between the two groups (P > 0.05). Parecoxib had no significant negative effect on early postoperative cognitive function, effectively alleviating early postoperative acute pain without increasing postoperative complications. The findings have implications for the broader use of parecoxib in postoperative pain management in elderly patients undergoing major surgery.

## Linked entities

- **Chemicals:** parecoxib (PubChem CID 119828)

## Full-text entities

- **Diseases:** inflammatory (MESH:D007249), postoperative complications (MESH:D011183), pain (MESH:D010146), postoperative acute pain (MESH:D010149), gastrointestinal cancer (MESH:D005770), POCD (MESH:D000079690), Neuroinflammation (MESH:D000090862)
- **Chemicals:** Parecoxib (MESH:C409945)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12010987/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12010987/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12010987/full.md

---
Source: https://tomesphere.com/paper/PMC12010987